Linagliptin and Metformin (Jentadueto)
Dipeptidyl Peptidase 4 Inhibitor class · 4 generic manufacturers · 12 ANDAs filed at FDA.
Questions a plan sponsor actually asks.
What is Linagliptin and Metformin used for?
Linagliptin and Metformin is tracked in Medicare Part D. Specific indication information is not available in our current dataset.
Is there a generic for Linagliptin and Metformin?
Yes. 12 ANDAs filed at FDA, 4 generic manufacturers currently shipping.
How much does my plan pay for Linagliptin and Metformin?
Across 329 Part D plans, Linagliptin and Metformin averages $10.15/unit (NADAC). Lowest available: $8.44/unit. Highest in distribution: $16.95/unit.
Is Linagliptin and Metformin on the FDA shortage list?
No. Linagliptin and Metformin is not currently on the FDA Drug Shortage Database.
6 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (10 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.